NASHVILLE, Tenn., March 19, 2013 /PRNewswire/ -- The first two installations of Apoteca in the United States took place at the Cleveland Clinic and Wake Forest University Baptist Medical Center. Cleveland Clinic's implementation plan included a lengthy review and approval by the Ohio Board of Pharmacy. Both facilities deployed Apoteca in busy oncology centers serving both inpatients and outpatients. Daily production includes complex doses that require reconstitution, multiple vials, bags requiring final volume adjustment, and products requiring delicate handling, like monoclonal agents.
Next month, the University of Maryland Medical System will take delivery and install the next Apoteca. The University of Maryland joins the number of worldwide pharmacies in active daily production with APOTECAchemo™, where safety, efficiency, workload relief and cost reduction are being realized in one elegant package.
Another critically important achievement at Cleveland Clinic was the activation of an HL-7 interface with Epic's healthcare information system, eliminating duplicate entry and the related risk of transcription errors. Wake Forest will deploy a similar interface to Epic.
Production has continued to grow, reaching about 75% to 80% of daily volume, and is expected to increase further, as seen in other Apoteca installations making over 100 doses per day. Each site chooses from nearly 60 chemical entities and 300 different vials supported by Apoteca, allowing the selection of products that provide maximum benefit. Apoteca's flexibility has also helped protect against drug shortages by efficiently switching to alternate sources.
Importantly, Apoteca is supported by an experienced service organization with more than 25 years of success in industrial engineering, healthcare and robotics, resulting in documented up-time percentages of 98.5% or higher. Excellent support and product maturity also makes installation easier than one might think. At Wake Forest, for example, installation from loading dock to making initial patient doses took fewer than 30 days.
Confidence continues to grow in Apoteca's onboard patient and staff safety features. Apoteca includes the scientific elements of other standalone products using balances, scanners and cameras for validation and documentation. It promotes staff safety and cost control through physical separation of humans from the compounding process, without requiring certain closed system transfer devices. This elimination represents a cost-saving opportunity of $10.00 to $12.00 per dose.
For more information please visit: www.ApotecaUSA.com